SYRS - Syros Pharmaceuticals Inc Stock Price, Fair Value and News

$0.240.00 (0.00%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

SYRS Price Action

Last 7 days

-7.7%

Last 30 days

-90.8%

Last 90 days

-84.6%

Trailing 12 Months

-94.2%

SYRS RSI Chart

SYRS Valuation

Market Cap

6.4M

Price/Earnings (Trailing)

-0.07

Price/Sales (Trailing)

0.65

Price/Free Cashflow

-0.06

SYRS Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

SYRS Fundamentals

SYRS Revenue

Revenue (TTM)

9.9M

SYRS Earnings

Earnings (TTM)

-97.8M

Earnings Growth (Yr)

84.07%

Earnings Growth (Qtr)

72.58%

SYRS Profitability

Return on Equity

879.39%

Return on Assets

-115.08%

Free Cashflow Yield

-1.6K%

SYRS Investor Care

Buy Backs (1Y)

3.88%

Diluted EPS (TTM)

-3.07

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	13.6M	12.4M	11.2M	9.9M
2022	24.1M	25.2M	23.4M	14.9M
2021	17.5M	19.5M	21.4M	23.5M
2020	3.9M	6.6M	9.9M	15.1M
2019	2.1M	2.2M	2.4M	2.0M
2018	370.0K	745.0K	1.2M	2.0M
2017	684.0K	1.1M	1.4M	1.1M
2016	0	0	0	317.0K
2015	0	0	0	317.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About Syros Pharmaceuticals Inc

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.

CEO	Dr. Nancy A. Simonian M.D.
WEBSITE	syros.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	117

Syros Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Syros Pharmaceuticals Inc? What does SYRS stand for in stocks?

SYRS is the stock ticker symbol of Syros Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Syros Pharmaceuticals Inc (SYRS)?

As of Mon Dec 09 2024, market cap of Syros Pharmaceuticals Inc is 6.44 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SYRS stock?

You can check SYRS's fair value in chart for subscribers.

Is Syros Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether SYRS is over valued or under valued. Whether Syros Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Syros Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SYRS.

What is Syros Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Dec 09 2024, SYRS's PE ratio (Price to Earnings) is -0.07 and Price to Sales (PS) ratio is 0.65. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SYRS PE ratio will change depending on the future growth rate expectations of investors.